CD8A and cancer: Interestingly, Dammeijer et al. found in mouse models that PD-L1+ cDC2s were a major target for anti-PD-L1 therapy in TDLNs, and that PD-L1+ cDC2s modulate CD8+ T cell function in a way that breaks with conventional knowledge, suggesting that targeting and modulating cDC2s can also enhance cancer immunotherapy[163].